Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Company Promoters:
Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and AKW WBL Family Pvt Trust are the company promoters.
Company Financials:
| Particulars | For the year/period ended (₹ in million) | |||
|---|---|---|---|---|
| 31-Dec-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
| Total Assets | 3,158.83 | 3,384.88 | 2,981.80 | 2,898.87 |
| Total Revenue | 3,230.94 | 3,313.39 | 3,115.25 | 3,565.76 |
| Profit After Tax | 96.74 | 162.13 | 638.22 | 111.98 |
Windlas Biotech IPO Date & Price Band
| IPO Open: | 04 August 2021 |
| IPO Close: | 06 August 2021 |
| IPO Size: | Approx ₹401.54 Crores |
| Fresh Issue: | Approx ₹165 Crores |
| Offer for Sale: | Approx ₹236.54 Crores – 5,142,067 Equity Shares |
| Face Value: | ₹5 Per Equity Share |
| Price Band: | ₹448 to ₹460 Per Share |
| Listing on: | BSE & NSE |
| Retail Portion: | 35% |
Windlas Biotech IPO Market Lot
The Windlas Biotech IPO minimum market lot is 30 shares with ₹13,800 application amount. The retail investors can apply up-to 14 lots, 420 shares with ₹193.200 application amount.
| Minimum Lot Size: | Minimum 30 Shares |
| Minimum Amount: | ₹13,800 |
| Maximum Lot Size: | Maximum 420 Shares |
| Maximum Amount: | ₹193,200 |
Windlas Biotech IPO Date, Time Table, Allotment & Listing
The Windlas Biotech IPO date is 04 August 2021 and the IPO close date is 06 August 2021. The allotment date is 11 August 2021 and the IPO may list on 17 August 2021.
| Price Band Announcement: | 30 July 2021 |
| Anchor Investors Allotment: | 03 August 2021 |
| IPO Open Date: | 04 August 2021 |
| IPO Close Date: | 06 August 2021 |
| Basis of Allotment: | 11 August 2021 |
| Refunds: | 12 August 2021 |
| Credit to Demat Account: | 13 August 2021 |
| IPO Listing Date: | 17 August 2021 |
Windlas Biotech IPO Registrar
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083
Phone: +91-22-4918 6270
Email: windlas.ipo@linkintime.co.in
Website: http://www.linkintime.co.in
Note: Check Windlas Biotech IPO allotment status on Linkintime website allotment URL. Click Here
Windlas Biotech IPO Lead Managers
- DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd)
- IIFL Holdings Limited
- SBI Capital Markets Limited
Company Address
Windlas Biotech Limited
40/1, Mohabewala Industrial Area,
Dehradun, 248110
Phone: +91 135 6608000
Email: grievance@windlasbiotech.com
Website: http://www.windlasbiotech.com/